Leukapheresis Products Market Research Report - Forecast till 2027

Leukapheresis Products Market Research Report: By Type (Leukapheresis Devices, Leukapheresis Disposables), Application (Research Applications, Therapeutic Applications), End User (Blood Component Provider and Blood Center, Other) -Forecast Till 2027

ID: MRFR/MED/5303-HCR | January 2023 | Region: Global | 90 Pages         

Leukapheresis Products Market Speak to Analyst Request a Free Sample

Leukapheresis Products Market

Leukapheresis Products Market is expected to hold a value of about USD 19.2 Million with CAGR of 7.7% during the forecast period.

Segmentation
By Type Leukapheresis Devices Leukapheresis Disposables
By Application Research Applications Therapeutic Applications
By End User Blood Component Provider Blood Center Other
Key Players
Companies Profiled   Haemonetics   Terumo BCT   Asahi Kasei Medical   STEMCELL Technologies   Macopharma   Caltag Medsystem   ZENBIO   Fresenius Kabi   PPA Research Group   StemExpress
Drivers
Market Driving Forces   Growing number of blood donations Increasing prevalence of leukaemia   Demand for leukapheresis products in clinical research
Request a Free Sample

Leukapheresis Products Market Overview Leukapheresis products market is anticipated that the market held a market value of USD 19.2 million in 2017 and is projected to grow at a CAGR of 7.7% over the forecast period. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs). Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia. Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.

Segmentation:


The leukapheresis products market has been segmented into type, application, and end user. On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.


The market, on the basis of application, has been segmented into research applications and therapeutic applications.


On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others are some of the key players in the  leukapheresis products market.


Regional Market Summary: Global Leukapheresis Products Market Share (%), by Region, 2017 Leukapheresis Products Market  Share


Source: America’s Blood Centers, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.


Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.


The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.


The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.Recent Development


Cryoport Inc. and Cell Matters SA formed a strategic agreement in February 2022 to provide end-to-end cryopreservation services for leukapheresis-derived therapies in the life sciences industry, enabling both autologous and allogeneic cell therapies. Terumo Blood and Cell Technologies revealed in July 2021 that physicians would be able to perform extracorporeal photopheresis immunotherapy (ECP) operations at the patient's bedside. Spectra Optia's functionality has been enhanced by the firm. These devices can now be used to perform the UVA PIT System ECP as a functionally closed, online, multistep system using mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.

Leukapheresis Products Market, by Type



  • Leukapheresis Devices

  • Apheresis Devices

  • Leukapheresis Columns & Cell Separators

  • Leukoreduction Filters



  • Leukapheresis Disposables


Leukapheresis Products Market, by Application



  • Research Applications

  • Therapeutic Applications


Leukapheresis Products Market, by End User



  • Blood Component Providers and Blood Centers

  • Hospitals and Transfusion Centers

  • Others


Leukapheresis Products Market, by Region




  • Americas


    • North America

      • US

      • Canada



    • South America




  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe




  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • The Middle East & Africa

    • Middle East

    • Africa




Leukapheresis Products Market, by Key Players



  • Haemonetics

  • Terumo BCT

  • Asahi Kasei Medical

  • STEMCELL Technologies

  • Macopharma

  • Caltag Medsystem

  • ZENBIO

  • Fresenius Kabi

  • PPA Research Group

  • StemExpress

  • HemaCare Corporation

  • ALLCells, LLC

  • Others


Intended Audience



  • Apheresis Device Manufacturers and Distributors

  • Leukapheresis Product Manufacturers and Distributors

  • Pharmaceutical and Biotechnological Companies

  • Healthcare Service Providers (including Hospitals and Transfusion Centers)

  • Cancer Treatment Centers

  • Blood Component Providers & Blood Centers

  • Contract Research Organizations

  • Academic and Research Institutes

  • Government Associations



Report Scope:

Report Attribute/Metric Details
  Market Size

  • 2017: USD 19.2 Million
  • 2027: Significant Value
  •   CAGR   7.7% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Application and End user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Growing number of blood donations Increasing prevalence of leukaemia
  • Demand for leukapheresis products in clinical research


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The leukapheresis products market is projected to grow at a 7.7% CAGR between 2018-2023.

    The Americas is projected to command the largest share in the leukapheresis products market.

    Rising prevalence of leukemia is boosting market growth.

    Different strategies used by market players to create a dominance in the leukapheresis products market include product launches, collaborations, strategic alliances, and others.